Compounds > gefitinib
Page last updated: 2024-09-03

gefitinib and pki 166

gefitinib has been researched along with pki 166 in 6 studies

Compound Research Comparison

Studies
(gefitinib)		Trials
(gefitinib)		Recent Studies (post-2010)
(gefitinib)		Studies
(pki 166)		Trials
(pki 166)		Recent Studies (post-2010) (pki 166)
5,2315662,91954110

Research

Studies (6)

TimeframeStudies, this research(%)All Research%
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's6 (100.00)29.6817
2010's0 (0.00)24.3611
2020's0 (0.00)2.80

Authors

AuthorsStudies
Fry, DW; Slichenmyer, WJ1
Baselga, J; Hammond, LA1
Grünwald, V; Hidalgo, M1
Aunoble, B; Bourhis, J; Rolhion, C; Tortochaux, J1
Berlin, JD; Lockhart, AC; Lockhart, C1
Ganti, AK; Potti, A1

Reviews

6 review(s) available for gefitinib and pki 166

ArticleYear
Anticancer therapy targeting the erbB family of receptor tyrosine kinases.
    Seminars in oncology, 2001, Volume: 28, Issue:5 Suppl 16

    Topics: Animals; Antibodies, Bispecific; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Breast Neoplasms; Cetuximab; Enzyme Inhibitors; ErbB Receptors; Erlotinib Hydrochloride; Gefitinib; Humans; Protein-Tyrosine Kinases; Pyrimidines; Pyrroles; Quinazolines; Receptor, ErbB-2; Trastuzumab

2001
HER-targeted tyrosine-kinase inhibitors.
    Oncology, 2002, Volume: 63 Suppl 1

    Topics: Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Clinical Trials as Topic; Enzyme Inhibitors; ErbB Receptors; Erlotinib Hydrochloride; Female; Gefitinib; Head and Neck Neoplasms; Humans; Lung Neoplasms; Morpholines; Ovarian Neoplasms; Protein-Tyrosine Kinases; Pyrimidines; Pyrroles; Quinazolines; Receptor, ErbB-2

2002
Developing inhibitors of the epidermal growth factor receptor for cancer treatment.
    Journal of the National Cancer Institute, 2003, Jun-18, Volume: 95, Issue:12

    Topics: Aminoquinolines; Aniline Compounds; Animals; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Cetuximab; Clinical Trials as Topic; Drug Design; Drugs, Investigational; ErbB Receptors; Erlotinib Hydrochloride; Gefitinib; Gene Expression Regulation, Neoplastic; Humans; Morpholines; Neoplasms; Organic Chemicals; Panitumumab; Pyrimidines; Pyrroles; Quinazolines; Signal Transduction; Structure-Activity Relationship

2003
[Targeting of epidermal growth factor receptor and applications in ORL cancer].
    Bulletin du cancer, 2003, Volume: 90 Spec No

    Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Carcinoma, Squamous Cell; Cetuximab; ErbB Receptors; Erlotinib Hydrochloride; Gefitinib; Humans; Morpholines; Neoplasm Proteins; Otorhinolaryngologic Neoplasms; Protein-Tyrosine Kinases; Pyrimidines; Pyrroles; Quinazolines

2003
The epidermal growth factor receptor as a target for colorectal cancer therapy.
    Seminars in oncology, 2005, Volume: 32, Issue:1

    Topics: Aminoquinolines; Aniline Compounds; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Cell Transformation, Neoplastic; Cetuximab; Colorectal Neoplasms; Disease Progression; ErbB Receptors; Erlotinib Hydrochloride; Gefitinib; Humans; Lapatinib; Organic Chemicals; Panitumumab; Prognosis; Pyrimidines; Pyrroles; Quinazolines; Signal Transduction

2005
Epidermal growth factor inhibition in solid tumours.
    Expert opinion on biological therapy, 2005, Volume: 5, Issue:9

    Topics: Administration, Oral; Animals; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Cetuximab; Colorectal Neoplasms; Drug Delivery Systems; Drug Evaluation, Preclinical; ErbB Receptors; Erlotinib Hydrochloride; Gefitinib; Humans; Lung Neoplasms; Panitumumab; Protein Kinase Inhibitors; Pyrimidines; Pyrroles; Quinazolines; Randomized Controlled Trials as Topic

2005